- Home
- NIU vs IMAB Comparison
NIU vs IMAB Comparison
Compare NIU & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- IMAB
- Stock Information
- Founded
- NIU 2014
- IMAB 2014
- Country
- NIU China
- IMAB United States
- Employees
- NIU N/A
- IMAB N/A
- Industry
- NIU Auto Manufacturing
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NIU Consumer Discretionary
- IMAB Health Care
- Exchange
- NIU Nasdaq
- IMAB Nasdaq
- Market Cap
- NIU 216.7M
- IMAB 200.9M
- IPO Year
- NIU 2018
- IMAB 2020
- Fundamental
- Price
- NIU $3.42
- IMAB $2.29
- Analyst Decision
- NIU
- IMAB Strong Buy
- Analyst Count
- NIU 0
- IMAB 2
- Target Price
- NIU N/A
- IMAB $6.00
- AVG Volume (30 Days)
- NIU 1.1M
- IMAB 1.0M
- Earning Date
- NIU 08-11-2025
- IMAB 05-15-2025
- Dividend Yield
- NIU N/A
- IMAB N/A
- EPS Growth
- NIU N/A
- IMAB N/A
- EPS
- NIU N/A
- IMAB N/A
- Revenue
- NIU $477,578,753.00
- IMAB N/A
- Revenue This Year
- NIU $41.32
- IMAB N/A
- Revenue Next Year
- NIU $24.38
- IMAB N/A
- P/E Ratio
- NIU N/A
- IMAB N/A
- Revenue Growth
- NIU 26.51
- IMAB N/A
- 52 Week Low
- NIU $1.66
- IMAB $0.60
- 52 Week High
- NIU $4.90
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- NIU 47.60
- IMAB 53.66
- Support Level
- NIU $3.31
- IMAB $2.00
- Resistance Level
- NIU $3.77
- IMAB $2.95
- Average True Range (ATR)
- NIU 0.22
- IMAB 0.35
- MACD
- NIU -0.02
- IMAB -0.07
- Stochastic Oscillator
- NIU 37.04
- IMAB 30.53
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).